- Jun 18
- 7 min read
Updated: 4 days ago
Introduction
The morning Wei Chen (alias) received his diagnosis, he and his wife had been married less than a year.
He was 35. They were still in that early, luminous phase of marriage — learning each other’s habits, building a home, making quiet plans for the future. Then, in October 2020, a blood test changed everything. The results came back: acute myeloid leukemia, M5 subtype. A bone marrow examination showed that 82.5% of his marrow cells were abnormal blasts — immature, malignant cells that had taken over where healthy blood should have been forming.
The number didn’t mean much to Wei at first. Then the doctor explained what it meant.
About The Patient
Wei was not the kind of man who talked much about fear. His wife would later describe him as steady — the sort of person who fixed things, who found solutions. He moved through the world quietly and purposefully. Illness, in his mind, was something that happened to other people.
But acute myeloid leukemia (AML) — a fast-moving cancer of the blood and bone marrow — does not negotiate with a person’s character. It requires time, precision, and a body willing to respond to treatment. Wei’s body, it turned out, was not responding.
When the Treatment Stopped Working
Wei’s oncologists began two cycles of standard chemotherapy. For most AML patients, this is the critical first step — it aims to push the disease into remission before a bone marrow transplant becomes possible. But when his follow-up bone marrow biopsy came back, the results were devastating. The blast count hadn’t fallen. It had climbed — to 69%. Worse, the treatment had triggered serious complications: intestinal infection, septic shock, and gastrointestinal bleeding. His body had endured the full force of chemotherapy, and the disease had barely flinched.
His wife sat with him through those nights. Family members came to help make decisions, voices filling the room with worry. Wei listened. He said little. But somewhere underneath the silence, he was already looking for another path.
A Decision Made in Fear, and in Hope
In May 2020, Wei and his wife travelled to a JCI-accredited hospital in Hebei, China — one of the country’s leading centres for blood cancer treatment and bone marrow transplantation. He was admitted under the care of Dr. Zhao Jiaru (alias), director of the hospital’s Bone Marrow Transplant Unit.
It was not an easy decision. There were long conversations, late nights, and a family that loved him weighing every option. The road to Hebei was built from desperation and hope in equal measure. But Wei had run out of alternatives closer to home. He made the leap.
If you'd like to understand how accessing a Chinese specialist through ChinaCureLink works, our team can walk you through the process at no cost. |
Inside the Treatment
Understanding the Disease in Full
The first thing Dr. Zhao’s team did was build a complete, high-resolution picture of Wei’s disease. A comprehensive MICM-PP diagnostic workup — a multi-dimensional assessment examining the leukemia’s cell morphology, immune markers, chromosomes, and molecular genetics — told a complicated story.
Immunophenotyping confirmed that 52.9% of Wei’s marrow cells were malignant monocytic blasts. His molecular panel revealed two findings that placed him in a particularly high-risk category: a NUP98-NSD1 fusion gene (present at 37.7%) and mutations in both RUNX1 and FLT3-ITD. This combination is associated with resistance to chemotherapy and an elevated risk of relapse. A spinal fluid examination then found leukemic cells in his central nervous system — meaning the disease had spread beyond the bone marrow and was now circulating in the fluid surrounding his brain and spine.
The picture was serious. Dr. Zhao had seen patients like Wei before. She had a plan.
A Tailored Protocol
The team initiated a carefully personalised approach: low-dose chemotherapy combined with targeted agents to reduce the tumour burden, without subjecting Wei’s already-stressed body to another high-intensity regimen. Simultaneously, intrathecal injections — chemotherapy delivered directly into the spinal canal — were administered to address the CNS involvement. And without delay, a search request was submitted to the China Bone Marrow Donor Registry.
A follow-up biopsy three weeks later was sobering. Blast counts remained high, and the NUP98-NSD1 fusion gene had risen to 53%. Dr. Zhao made a decisive call: salvage transplantation — proceeding with a stem cell transplant even before achieving complete remission. A higher-risk path, but for Wei, the only realistic route to long-term survival.
“For patients with difficult-to-treat AML, salvage transplantation is not a last resort born of desperation. It is an active, considered decision. For this patient, it was the most important thing we could do.”
The Match That Changed Everything
Then came a stroke of rare good fortune. The bone marrow registry found Wei a fully matched unrelated donor — a 10 out of 10 HLA match, the best possible tissue compatibility between donor and recipient. For Wei, it felt like the first thing that had gone right in months.
The transplant proceeded. Eleven days later, the donor platelets began to engraft — to take hold and begin producing cells in Wei’s marrow. By day fourteen, white cell counts confirmed full engraftment. A new immune system was establishing itself.
Navigating the Complications
The weeks after transplant were not without difficulty. Wei developed cytomegalovirus (CMV) viremia — a viral reactivation that commonly occurs when the immune system is deliberately suppressed post-transplant — and acute graft-versus-host disease (GVHD) affecting his skin. GVHD occurs when donor immune cells, still learning to recognise their new host, mount a reaction against the patient’s own tissues. Both were managed: antiviral therapy addressed the CMV, and adjustments to his immunosuppressive medications brought the GVHD under control.
One month post-transplant, a bone marrow evaluation confirmed what everyone had hoped for: complete remission. The malignant cells were undetectable.
Three months out, Wei developed a milder chronic GVHD involving his skin and liver — a common late complication that, paradoxically, also signals that the donor immune cells are active and vigilant, reducing relapse risk. Medications were adjusted again, and targeted maintenance agents were added. Slowly, carefully, Wei’s body found its new equilibrium.
Two Years Later
Two years after his transplant, Wei returned to the hospital for his annual review. He came with his wife. Just the two of them this time — no anxious relatives, no hushed family meetings. His disease was stable. His blood counts were normal. His life had quietly reassembled itself around him.
In Their Own Words
Dr. Huang Lu (alias), the attending physician on Wei’s case, reflected on watching the couple walk back through the doors of the clinic two years on:
“I remember when they first came to us — the room was full of family members, everyone taking turns discussing what to do, and underneath all of it you could feel how frightened everyone was. Even when the path forward is clear, even when you know that a transplant is the only real option, there is still this fear you have to walk through. What we can do is walk with the patient. We can be certain when they cannot. Two years later, seeing them come back like this — just the two of them, no more fear in the room — that is why we do this work.”
Wei himself is quieter about the whole experience. When asked what he would say to someone facing a similar diagnosis, he thought for a moment.
“Find people who know what they’re doing. And then trust them.”
His wife smiled at that. It was, she said later, the most he’d spoken about the whole thing in months. He was, in the way she’d always known him, already looking forward.
The Chinese specialist team had identified a 10/10 HLA-matched unrelated donor through the Chinese Bone Marrow Donor Registry — a full match across all ten key human leukocyte antigen markers. This level of compatibility is considered optimal for allogeneic (donor-based) stem cell transplants and significantly reduces the risk of graft rejection.
What This Story Means
For patients with refractory acute myeloid leukemia, the window for successful treatment is narrow and the margin for error is thin. Wei’s story is not a guarantee — it is a reminder that within that window, with the right diagnosis, the right team, and a transplant undertaken with both courage and precision, lives can be fully reclaimed.
Some roads back are longer than you expect. Some have complications along the way. But they lead somewhere real.
What Patients Say About ChinaCureLink & Medebound HEALTH
ChinaCureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
About ChinaCureLink
ChinaCureLink helps patients across the world — access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top 5 cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team that understands both the medical and cultural needs of Southeast Asian patients.
ChinaCureLink is proudly affiliated with Medebound HEALTH— an international medical concierge company headquartered in New York, specialized in securing premium second opinions from top US hospitals and specialists. With over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized as one of the leading patient access services across North America and the Asia Pacific, Medebound HEALTH brings the same standard of expert care coordination to every patient we serve.
This article is for informational purposes only and does not constitute medical advice. All treatment decisions should be made in consultation with a qualified oncologist who has reviewed your complete medical history and current diagnostic information.
Comments